Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Assembly Biosciences Announces Upcoming Investor Conference Presentations GlobeNewswire - Thu May 28, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 27.66 (-0.25%)
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Tue May 26, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 27.66 (-0.25%)
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Fri May 22, 6:05AM CDT

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases,...

ASMB : 27.66 (-0.25%)
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases GlobeNewswire - Fri May 22, 6:00AM CDT

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN...

ASMB : 27.66 (-0.25%)
MarketBeat.com
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference MarketBeat - Thu May 14, 6:05AM CDT

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing...

ASMB : 27.66 (-0.25%)
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 GlobeNewswire - Wed May 13, 1:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

ASMB : 27.66 (-0.25%)
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference GlobeNewswire - Mon May 11, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

ASMB : 27.66 (-0.25%)
Assembly Biosciences: Q1 Earnings Snapshot AP - Thu May 7, 3:08PM CDT

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 27.66 (-0.25%)
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights GlobeNewswire - Thu May 7, 3:00PM CDT

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule...

ASMB : 27.66 (-0.25%)
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 GlobeNewswire - Thu Apr 9, 7:00AM CDT

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...

ASMB : 27.66 (-0.25%)

Barchart Exclusives

Why Cathie Wood Is Pounding the Table for $750,000 Bitcoin: A New Generation Loves Crypto to Hedge Against Inflation Barchart - Sat May 30, 2:00PM CDT
The star fund manager believes that the crypto's price can reach $1.25 million per coin. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.